



August 21, 2019

Listing Department BSE LIMITED P J Towers, Dalal Street, Fort, Mumbai–400 001

Code: 532 321

Listing Department **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), <u>Mumbai-400 051</u> Code: CADILAHC

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated August 21, 2019 titled "Zydus receives final approval from the USFDA for Ranolazine Extended-Release Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,


Yours faithfully,

For, CADILA HEALTHCARE LIMITED

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above





Zydus receives final approval from the USFDA for Ranolazine Extended-Release Tablets

Ahmedabad, 21 August, 2019

Zydus Cadila has received the final approval from the USFDA to market Ranolazine Extended-Release Tablets (US RLD- Ranexa[®]), 500 mg and 1,000 mg. The drug is used to treat chronic angina and may be used with other medicines that are used for heart problems and blood pressure control. It will be manufactured at the group's formulations manufacturing facility at Baddi.

The group now has 271 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapics. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
